BIDMC Researchers Develop Decision-Making Tool to Benefit Patients with HCV
Beth Israel Lahey HealthBIDMC researchers led a retrospective analysis of four randomized clinical trials focused on the effects of DAA therapies in patients with HCV-associated liver failure and developed a new means of predicting improvement in liver function in response to DAA treatment.